Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after elective total knee replacement
2004-001317-34Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dabigatran and enoxaparin in venous thromboembolism (VTE) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of total venous thromboembolic events and all-cause mortality during treatment. Started Sep 2004; status: completed.
02
Drugs
dabigatranenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2004-001317-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001317-34.